Mega Cap
Drug Manufacturers - General
Stocks Ranked by
Market Capitalization
| Name | Market cap | Price |
Price change % |
|
|---|---|---|---|---|
1
Eli Lilly
LLY
$1.12T
| $1.12T | $1,253.25 | 0.3% |
|
2
Johnson & Johnson
JNJ
$612B
| $612B | $254.05 | 0.59% |
|
3
AbbVie
ABBV
$505B
| $505B | $285.75 | 0.12% |
|
4
Merck
MRK
$361B
| $361B | $146.35 | 0.27% |
|
5
Novartis
NVS
$286B
| $286B | $150.34 | 0.19% |
|
6
AstraZeneca
AZN
$256B
| $256B | $165.26 | 0.09% |
|
7
Amgen
AMGN
$234B
| $234B | $432.40 | 0.02% |
|
Mega Cap Drug Manufacturers - General Stocks at a Glance
Large drug manufacturers sell diversified portfolios of branded medicines backed by deep development pipelines. Patent lives set the clock: blockbuster franchises fund the R&D and acquisitions needed to outrun expirations, supporting durable margins and dividends.
There are 7 mega cap Drug Manufacturers - General stocks — companies in the Drug Manufacturers - General industry with a market cap over $200B — worth a combined $3.37T.
The largest by market cap are Eli Lilly (LLY) at $1.12T, Johnson & Johnson (JNJ) at $612B and AbbVie (ABBV) at $505B.
Among institutional investors, Eli Lilly (LLY) drew the most net new fund positions in Q2 2026: 418 funds opened new positions, taking total fund holders up 256 (5.8%) quarter-over-quarter.
- Combined market cap: $3.37T across 7 stocks.
- Mega Cap: market cap over $200B.
- Largest constituent: Eli Lilly (LLY), $1.12T market cap.
- Most net new fund positions in Q2 2026: Eli Lilly (LLY), +256 holders.
Market caps and prices updated daily; fund activity based on aggregated SEC 13F filings for Q2 2026.